Functional consequences of PRPF39 on distant genes and cisplatin sensitivity

Human Molecular Genetics

Volumn 21, Issue 19, 2012, Pages 4348-4355

  Stark, Amy L ^a   Delaney, Shannon M ^a   Wheeler, Heather E ^a   Im, Hae Kyung ^a   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; CISPLATIN; MAP3K4 PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PRPF39 PROTEIN; SMALL INTERFERING RNA; TFPD2 PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENETIC SUSCEPTIBILITY; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN; HUMAN CELL; IC 50; LYMPHOBLASTOID CELL LINE; NIGERIA; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

CISPLATIN; EPISTASIS, GENETIC; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HAPMAP PROJECT; HUMANS; NIGERIA; NUCLEAR PROTEINS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; QUANTITATIVE TRAIT LOCI; RNA-BINDING PROTEINS;

EID: 84866428890     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/dds266     Document Type: Article

References (36)

1. Rabik, C.A. and Dolan, M.E. (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat. Rev., 33, 9-23.
2. Travis, L.B., Beard, C., Allan, J.M., Dahl, A.A., Feldman, D.R., Oldenburg, J., Daugaard, G., Kelly, J.L., Dolan, M.E., Hannigan, R. et al. (2010) Testicular cancer survivorship: research strategies and recommendations. J. Natl Cancer Inst., 102, 1114-1130.
3. Ross, C.J., Katzov-Eckert, H., Dube, M.P., Brooks, B., Rassekh, S.R., Barhdadi, A., Feroz-Zada, Y., Visscher, H., Brown, A.M., Rieder, M.J. et al. (2009) Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat. Genet., 41, 1345-1349.
4. Brydoy, M., Oldenburg, J., Klepp, O., Bremnes, R.M., Wist, E.A., Wentzel-Larsen, T., Hauge, E.R., Dahl, O. and Fossa, S.D. (2009) Observational study of prevalence of long-term Raynaud-like phenomena and neurological side effects in testicular cancer survivors. J. Natl Cancer Inst., 101, 1682-1695.
5. Oldenburg, J., Kraggerud, S.M., Cvancarova, M., Lothe, R.A. and Fossa, S.D. (2007) Cisplatin-induced long-term hearing impairment is associated with specific glutathione S-transferase genotypes in testicular cancer survivors. J. Clin. Oncol., 25, 708-714.
6. Caronia, D., Patino-Garcia, A., Milne, R.L., Zalacain-Diez, M., Pita, G., Alonso, M.R., Moreno, L.T., Sierrasesumaga-Ariznabarreta, L., Benitez, J. and Gonzalez-Neira, A. (2009) Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients. Pharmacogenomics J., 9, 347-353.
7. Fukushima-Uesaka, H., Saito, Y., Maekawa, K., Kurose, K., Sugiyama, E., Katori, N., Kaniwa, N., Hasegawa, R., Hamaguchi, T., Eguchi-Nakajima, T. et al. (2009) Genetic polymorphisms of copper-and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab. Pharmacokinet., 24, 565-574.
8. Zhang, W., Duan, S., Kistner, E.O., Bleibel, W.K., Huang, R.S., Clark, T.A., Chen, T.X., Schweitzer, A.C., Blume, J.E., Cox, N.J. et al. (2008) Evaluation of genetic variation contributing to differences in gene expression between populations. Am. J. Hum. Genet., 82, 631-640.
9. Huang, R.S., Duan, S., Shukla, S.J., Kistner, E.O., Clark, T.A., Chen, T.X., Schweitzer, A.C., Blume, J.E. and Dolan, M.E. (2007) Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am. J. Hum. Genet., 81, 427-437.
10. Shukla, S.J., Duan, S., Badner, J.A., Wu, X. and Dolan, M.E. (2008) Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet. Genomics, 18, 253-262.
11. O'Donnell, P.H., Gamazon, E., Zhang, W., Stark, A.L., Kistner-Griffin, E.O., Stephanie Huang, R. and Eileen Dolan, M. (2010) Population differences in platinum toxicity as a means to identify novel genetic susceptibility variants. Pharmacogenet. Genomics, 20, 327-337.
12. Gamazon, E.R., Huang, R.S., Cox, N.J. and Dolan, M.E. (2010) Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl Acad. Sci. USA, 107, 9287-9292.
13. Cheung, V.G., Conlin, L.K., Weber, T.M., Arcaro, M., Jen, K.Y., Morley, M. and Spielman, R.S. (2003) Natural variation in human gene expression assessed in lymphoblastoid cells. Nat. Genet., 33, 422-425.
14. Morley, M., Molony, C.M., Weber, T.M., Devlin, J.L., Ewens, K.G., Spielman, R.S. and Cheung, V.G. (2004) Genetic analysis of genome-wide variation in human gene expression. Nature, 430, 743-747.
15. Cheung, V.G., Spielman, R.S., Ewens, K.G., Weber, T.M., Morley, M. and Burdick, J.T. (2005) Mapping determinants of human gene expression by regional and genome-wide association. Nature, 437, 1365-1369.
16. Smirnov, D.A., Morley, M., Shin, E., Spielman, R.S. and Cheung, V.G. (2009) Genetic analysis of radiation-induced changes in human gene expression. Nature, 459, 587-591.
17. Cheung, V.G., Nayak, R.R., Wang, I.X., Elwyn, S., Cousins, S.M., Morley, M. and Spielman, R.S. (2010) Polymorphic cis-and trans-regulation of human gene expression. PLoS Biol., 8, e1000480.
18. Wang, A., Forman-Kay, J., Luo, Y., Luo, M., Chow, Y.H., Plumb, J., Friesen, J.D., Tsui, L.C., Heng, H.H., Woolford, J.L. Jr. et al. (1997) Identification and characterization of human genes encoding Hprp3p and Hprp4p, interacting components of the spliceosome. Hum. Mol. Genet., 6, 2117-2126.
19. Cao, H., Wu, J., Lam, S., Duan, R., Newnham, C., Molday, R.S., Graziotto, J.J., Pierce, E.A. and Hu, J. (2011) Temporal and tissue specific regulation of RP-associated splicing factor genes PRPF3, PRPF31 and PRPC8-implications in the pathogenesis of RP. PLoS One, 6, e15860.
20. Comitato, A., Spampanato, C., Chakarova, C., Sanges, D., Bhattacharya, S.S. and Marigo, V. (2007) Mutations in splicing factor PRPF3, causing retinal degeneration, form detrimental aggregates in photoreceptor cells. Hum. Mol. Genet., 16, 1699-1707.
21. Chakarova, C.F., Hims, M.M., Bolz, H., Abu-Safieh, L., Patel, R.J., Papaioannou, M.G., Inglehearn, C.F., Keen, T.J., Willis, C., Moore, A.T. et al. (2002) Mutations in HPRP3, a third member of pre-mRNA splicing factor genes, implicated in autosomal dominant retinitis pigmentosa. Hum. Mol. Genet., 11, 87-92.
22. Graziotto, J.J., Inglehearn, C.F., Pack, M.A. and Pierce, E.A. (2008) Decreased levels of the RNA splicing factor Prpf3 in mice and zebrafish do not cause photoreceptor degeneration. Invest. Ophthalmol. Vis. Sci., 49, 3830-3838.
23. Mordes, D., Yuan, L., Xu, L., Kawada, M., Molday, R.S. and Wu, J.Y. (2007) Identification of photoreceptor genes affected by PRPF31 mutations associated with autosomal dominant retinitis pigmentosa. Neurobiol. Dis., 26, 291-300.
24. Song, E.J., Werner, S.L., Neubauer, J., Stegmeier, F., Aspden, J., Rio, D., Harper, J.W., Elledge, S.J., Kirschner, M.W. and Rape, M. (2010) The Prp19 complex and the Usp4Sart3 deubiquitinating enzyme control reversible ubiquitination at the spliceosome. Genes Dev., 24, 1434-1447.
25. Niehof, M. and Borlak, J. (2008) EPS15R, TASP1, and PRPF3 are novel disease candidate genes targeted by HNF4alpha splice variants in hepatocellular carcinomas. Gastroenterology, 134, 1191-1202.
26. Zhang, Y., Venkatraj, V.S., Fischer, S.G., Warburton, D. and Chellappan, S.P. (1997) Genomic cloning and chromosomal assignment of the E2F dimerization partner TFDP gene family. Genomics, 39, 95-98.
27. Lapouge, G., Millon, R., Muller, D., Abecassis, J., Eber, M., Bergerat, J.P. and Klein-Soyer, C. (2005) Cisplatin-induced genes as potential markers for thyroid cancer. Cell. Mol. Life Sci., 62, 53-64.
28. Abell, A.N., Granger, D.A. and Johnson, G.L. (2007) MEKK4 stimulation of p38 and JNK activity is negatively regulated by GSK3beta. J. Biol. Chem., 282, 30476-30484.
29. Wen, Y., Gorsic, L.K., Wheeler, H.E., Ziliak, D.M., Stephanie Huang, R. and Eileen Dolan, M. (2011) Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet. Genomics, 21, 471-488.
30. Abecasis, G.R., Cardon, L.R. and Cookson, W.O. (2000) A general test of association for quantitative traits in nuclear families. Am. J. Hum. Genet., 66, 279-292.
31. Browning, B.L. and Browning, S.R. (2009) A unified approach to genotype imputation and haplotype-phase inference for large data sets of trios and unrelated individuals. Am. J. Hum. Genet., 84, 210-223.
32. Stark, A.L., Zhang, W., Zhou, T., O'Donnell, P.H., Beiswanger, C.M., Huang, R.S., Cox, N.J. and Dolan, M.E. (2010) Population differences in the rate of proliferation of international HapMap cell lines. Am. J. Hum. Genet., 87, 829-833.
33. Huang, R.S., Kistner, E.O., Bleibel, W.K., Shukla, S.J. and Dolan, M.E. (2007) Effect of population and gender on chemotherapeutic agent-induced cytotoxicity. Mol. Cancer Ther., 6, 31-36.
34. Duan, S., Huang, R.S., Zhang, W., Bleibel, W.K., Roe, C.A., Clark, T.A., Chen, T.X., Schweitzer, A.C., Blume, J.E., Cox, N.J. et al. (2008) Genetic architecture of transcript-level variation in humans. Am. J. Hum. Genet., 82, 1101-1113.
35. R Development Core Team (2010) R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org/.
36. Pinheiro, J., Bates, D., DebRoby, S. and Sarkar, D., R Development Core Team (2011) nlme: Linear and Nonlinear Mixed Effects Models. R Package Version 3.1-98. http://cran.r-project.org/web/packages/nlme/cita tion.html.